STOCK TITAN

Notifications

Limited Time Offer! Get Platinum at the Gold price until January 31, 2026!

Sign up now and unlock all premium features at an incredible discount.

Read more on the Pricing page

[SCHEDULE 13D/A] Lineage Cell Therapeutics, Inc. SEC Filing

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13D/A
Rhea-AI Filing Summary

Lineage Cell Therapeutics (LCTX): Broadwood Partners, Broadwood Capital, and Neal C. Bradsher filed an amended Schedule 13D reporting updated ownership after the Issuer sold 12,000,000 common shares to Janus Henderson Investors in a block transaction under its at-the-market program, as described in a Form 8-K on November 12, 2025.

Broadwood Partners and Broadwood Capital each beneficially own 57,455,729 shares, representing 23.0% of the class. Mr. Bradsher beneficially owns 57,848,357 shares, or 23.1%, including stock options and warrants; he has sole voting and dispositive power over 392,628 shares and shared power over 57,455,729. Baselines reflect 250,222,274 and 250,527,274 shares outstanding, each as of the date hereof, as adjusted for the relevant derivative securities. No share transactions by the reporting persons occurred in the past sixty days. Purchases were funded by working capital and, for Mr. Bradsher, personal funds and director compensation.

Positive
  • None.
Negative
  • None.

Insights

Ownership updated to ~23% after issuer’s 12M-share sale.

Broadwood Partners, Broadwood Capital, and Neal C. Bradsher report beneficial ownership of 57,455,729 shares (23.0%) for the entities and 57,848,357 (23.1%) for Bradsher, including options/warrants. The amendment cites the Issuer’s sale of 12,000,000 shares to Janus Henderson Investors, which diluted percentage ownership.

The filing lists shared voting/dispositive power over 57,455,729 shares and Mr. Bradsher’s sole power over 392,628 shares. The outstanding share counts used are 250,222,274 and 250,527,274, each “as of the date hereof,” adjusted for derivative securities.

From an investment lens, this is a disclosure rather than a thesis change. Actual impact depends on future company actions and any subsequent ownership movements disclosed in later filings.






If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box.

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).






SCHEDULE 13D






SCHEDULE 13D






SCHEDULE 13D






SCHEDULE 13D


BROADWOOD PARTNERS, L.P.
Signature:By /s/ Neal C. Bradsher*
Name/Title:By Neal C. Bradsher/President of Broadwood Capital Inc.
Date:11/14/2025
BROADWOOD CAPITAL, INC.
Signature:By /s/ Neal C. Bradsher*
Name/Title:By Neal C. Bradsher/President
Date:11/14/2025
NEAL C. BRADSHER
Signature:By /s/ Neal C. Bradsher*
Name/Title:By Neal C. Bradsher
Date:11/14/2025
Comments accompanying signature:
* This Reporting Person disclaims beneficial ownership over the securities reported herein except to the extent of his or its pecuniary interest therein, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Attention: Intentional misstatements or omissions of fact constitute Federal criminal violations (see 18 U.S.C. 1001).

FAQ

What stake in LCTX does Broadwood report in this 13D/A?

Broadwood Partners and Broadwood Capital each report 57,455,729 shares, representing 23.0% beneficial ownership.

How many LCTX shares does Neal C. Bradsher beneficially own?

Mr. Bradsher reports 57,848,357 shares (23.1%), including stock options and warrants.

Why did Broadwood’s percentage ownership decrease?

The Issuer sold 12,000,000 shares to Janus Henderson Investors in a block transaction under its at-the-market program.

What voting power does Neal C. Bradsher have in LCTX?

He has sole voting/dispositive power over 392,628 shares and shared power over 57,455,729 shares.

Were there recent share transactions by the reporting persons?

The filing states there were no transactions in the past sixty days.

What share counts underpin the ownership percentages?

The filing references 250,222,274 and 250,527,274 shares outstanding as of the date hereof, adjusted for derivative securities.

How were the reported holdings funded?

Broadwood’s purchases came from working capital; Mr. Bradsher used personal funds and received certain shares as director compensation.
Lineage Cell The

NYSE:LCTX

LCTX Rankings

LCTX Latest News

LCTX Latest SEC Filings

LCTX Stock Data

414.59M
217.92M
0.42%
42.77%
11.84%
Biotechnology
Biological Products, (no Disgnostic Substances)
Link
United States
CARLSBAD